The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A.sub.3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient. The invention relates to compounds of the general formula (1) ##STR00001## wherein Y represents a group of the general formula (A), (B) or (C) ##STR00002## and all other symbols have the meanings as given in the description.